No Data
HUAKANG BIOMED (08622): Major shareholder Zhang Shuguang transfers 0.139 billion shares of common stock.
HUAKANG BIOMED (08622) published an announcement that the company received a notice from Zhang Shuguang, who is the company's executive director, the chairman of the Board of Directors, and...
Express News | Huakang Biomedical - Chairman Sold Entire Issued Share Capital in Crystal Grant
HUAKANG BIOMED (08622) plans to offer a placement at a discount of about 16%, aiming to raise a net amount of approximately 12.38 million HKD.
HUAKANG BIOMED (08622) announced that on December 31, 2024, the company intends to conduct a placement through the placement agent at a price of each...
Express News | Huakang Biomedical - to Place up to 100 Mln New Shares at HK$0.126 per Share
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
Huakang Biomedical Holdings Vice Chairman Yim Yang Chang Sells 31% Of Holding
No Data
